Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:DOI:10.1056/NEJMoa1415061, DOI:10.1056 NEJM e1503217, Saver, J.L.,et al, 2015
Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke
NEJM 372:DOI:10.1056 NEJMoa1503780, DOI:1056NEJM e1503217, Jovin, T.G.,et al, 2015
Bionic Reconstruction to Restore Hand Function After Brachial Plexus Injury: A Case Series of Three Patients
Lancet 385:2183-2189, Aszmann, O.C.,et al, 2015
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:2285-2295,2347, Saver, J.L.,et al, 2015
Thrombectomy within 8 hours after Symptom Onset in Ischemic Stroke
NEJM 372:2296-2306,2347, Jovin, T.G.,et al, 2015
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
Neurological Rehabilitation
Ann Neurol 32:695-699, Selzer,M.E., 1992
Newer Agents in the Treatment of Multiple Sclerosis
Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015
Drug-Resistant Epilepsy
NEJM 365:919-26, Kwan, P.,et al, 2011
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Human Natural Autoantibodies in the Treatment of Neurologic Disease
Neurol 72:1269-1276, Rodriguez,M.,et al, 2009
Effect of Laquinimod on MRI-Monitored Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIb Study
Lancet 371:2085-2092,2059, Comi,G.,etc., 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Multiple Sclerosis: New Insights and Trends
AJNR 27:954-957, Inglese,M., 2006
Multiple Sclerosis: The Role of MR Imaging
AJNR 27:1165-1176, Ge,Y., 2006
Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
Neurologist 12:171-178, Cree,B., 2006
Recent Developments in Neurology
BMJ 324:656-660, Wiebe,S.,&Nicolle,M.W., 2002
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
Imaging the Brain, Part 1 & 2
NEJM 338:812-820, 889-8961998., Gilman,S., 1998
Chromosome 19 Single-Locus & Multilocus Haplotype Assoc with MS, Evid of New Suscept Locus in Caucasian & Chinese Pts
JAMA 278:1256-1262, 12821997., Barcellos,L.F.,et al, 1997
Surgery for Seizures
NEJM 334:647-652, Engel,J.Jr., 1996
Spina Bifida
NEJM 387:444-450, Iskandar, B.J. & Finnell, R.H., 2022
The 5 Pillars in Tourette Syndrome Deep Brain Stimulation Patient Selection
Neurol 96:664-676, Martino, D.,et al, 2021
Stroke
Lancet 389:641-654, Hankey, G.J., 2017
Therapeutic Devices for Epilepsy
Ann Neurol 71:157-168, Fisher,R.S., 2012
Spinal Muscular Atrophy A Timely Review
Arch Neurol 68:979-984, Kolb, S.J.,et al, 2011
Diagnosis and Management of Motor Neurone Disease
BMJ 336:658-662, McDermott,C.J. &Shaw,P.J., 2008
Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006
Recent Advnaces in the Treatment of Epilepsy
Arch Neurol 60:929-935, Nguyen,D.K. &Spencer,S.S., 2003
Evolving Treatment Strategies for Epilepsy
JAMA 287:2917-2920, Diaz-Arrastia,R.,et al, 2002
Recommendations for the Establishment of Primary Stroke Centers
JAMA 283:3102-3109,3125, Alberts,M.J.,et al, 2000
Management of Epilepsy in Adolescents and Adults
Lancet 356:323-329, Brodie,M.J. & French,J.A., 2000
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
Further Evolution Toward Effective Therapy for Acute Ischemic Stroke
JAMA 279:1298-1303, 13041998., Fisher,M.&Bogousslavsky,J., 1998
Assessment of Vagus Nerve Stimulation for Epilepsy
Neurol 49:293-297, Fisher,R.S.,et al, 1997
New Antiepileptic Drugs:A Systematic Review of Their Efficacy and Tolerability
BMJ 313:1169-1174, 1157, 1158996., Marson,A.G.,et al, 1996
Management of Acoustic Neuroma
BMJ 311:1141-1144, Wright,A.&Bradford,R., 1995